P2.07-012 Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Response Evaluation in Solid Tumors (RECIST) criteria were developed to assess response to cytotoxic therapy. Response to immune checkpoint inhibitors depends on tumor and host factors including the presence of immune cells (IC) in the tumor environment. Organs differ in IC content. We hypothesized that nivolumab was more active in tumor lesions in IC rich than IC poor...